Tumour Suppressors· 2 min read

PTEN Loss Testing: Sequence, Copy Number and Protein Expression

PTEN restrains PI3K–AKT signalling. A PTEN result may come from sequencing, copy-number analysis or protein staining; each measures a different feature and has different limitations.

PTEN PIK3CA AKT1 MTOR

Quick Answer

PTEN restrains PI3K–AKT signalling. A PTEN result may come from sequencing, copy-number analysis or protein staining; each measures a different feature and has different limitations.

Mechanism map: the article’s main biological stages are separated from the final interpretation so a pathway relationship is not mistaken for a clinical conclusion.

What PTEN Does

PTEN can oppose PI3K signalling by acting on phosphoinositides. Loss of function can therefore shift the balance toward downstream AKT signalling.

What a Test Measures

A sequence variant, copy-number deletion and absent protein staining are not synonymous. Tumour purity, assay design and sample quality affect each result.

Key Takeaways

·Keep the test method with the PTEN result.
·PTEN findings need pathway and tumour context.
·A single test result does not determine treatment.

Put these genes in pathway context

PI3K–AKT–mTOR pathway

Frequently asked questions

What is the key idea in PTEN Loss Testing: Sequence, Copy Number and Protein Expression?

PTEN restrains PI3K–AKT signalling. A PTEN result may come from sequencing, copy-number analysis or protein staining; each measures a different feature and has different limitations.

What should be kept with the result or mechanism?

Keep the test method with the PTEN result. PTEN findings need pathway and tumour context. A single test result does not determine treatment.

References

1The PI3K pathway in human cancer. Nature Reviews Cancer, 2017. PubMed
2Pan-cancer analysis of PI3K pathway alterations. Nature Genetics, 2017. PubMed
3PIK3CA, PTEN and AKT alterations in cancer. Cancer Research, 2012. PubMed

Continue Reading

mTOR Signalling and Cancer Therapy

4 min read

PIK3CA, PTEN and AKT1 Alterations Compared

5 min read

The PI3K/AKT/mTOR Pathway in Cancer

4 min read

Top Tumor Suppressor Genes Explained

6 min read

PI3K Pathway Biomarkers: PIK3CA, PTEN, AKT1 and Beyond

3 min read

PTEN Hamartoma Tumour Syndrome: Germline PTEN Loss

3 min read

Choose your next research step

Move from this explanation into a gene profile, a pathway map, or the next evidence update.

Explore PTEN Open pathway context Track PTEN trials

PTEN has 40+ trials currently recruiting on ClinicalTrials.gov. The GeneAnalyses digest summarises the new and changed ones each day.